×
About 14,088 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,007 results

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally...
https://doi.org/10.1093/oncolo/oyac146
The Oncologist; Chang C, Li X et. al.

Aug 6th, 2022 - Systemic chemotherapy is the primary treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). More effective treatment options are highly awaited. The aim of this study was to evaluate the toxicity and fea...

A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgeneti...
https://doi.org/10.1007/s00266-022-03042-y
Aesthetic Plastic Surgery; Jia L, Xiong J et. al.

Aug 6th, 2022 - Microneedling refers to a minimally invasive technique that uses multiple fine needles targeted skin epidermis for mechanical stimulation to obtain therapeutic or cosmetic effects. It is suitable for the treatment of a variety of dermatological co...

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05129254

Aug 5th, 2022 - This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgen...

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT04594018

Aug 5th, 2022 - The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in the treatment of androgenetic alopecia.

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Aug 5th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  331 results see all →

Clinicaltrials.gov  434 results

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05129254

Aug 5th, 2022 - This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgen...

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT04594018

Aug 5th, 2022 - The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in the treatment of androgenetic alopecia.

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Aug 5th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Tailored Sonidegib Schedule After Complete Response in BCC
https://clinicaltrials.gov/ct2/show/NCT04806646

Aug 4th, 2022 - One cycle of therapy is defined as 28 days of sonidegib. The patient will start with first schedule. Treatment schedule 1 (TS1): assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alope...

Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05485571

Aug 3rd, 2022 - Alopecia areata (AA) is a common cause of non-cicatricial hair loss It is the second-most frequent non-scarring alopecia, after androgenic alopecia. The prevalence of the disease is 0.2% in the general population with higher prevelance in younger ...

see more →

News  848 results

Dermatologists Share Vitiligo Breakthrough News With Patients
https://www.medscape.com/viewarticle/978705

Aug 5th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a US Food and Drug Administration (FDA)-approved, easy-to-use to...

FDA Approves Trastuzumab-Deruxtecan (Enhertu) for HER2-Low Breast Cancer
https://www.medscape.com/viewarticle/978728

Aug 5th, 2022 - The US Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (Enhertu) for the treatment of patients with unresectable or metastatic HER2-low breast cancer. AstraZeneca's IV infusion is the first therapy approved for HER2-low brea...

Fast Five Quiz: Hair Loss (Alopecia)
https://www.medscape.com/viewarticle/977806

Aug 1st, 2022 - Hair loss (alopecia) is a common health concern for both men and women. Androgenetic alopecia is a genetically determined disorder. Affected individuals usually have a typical patterned distribution of hair loss. Alopecia areata is a recurrent non...

A toddler presents with patchy hair loss
https://www.mdedge.com/pediatrics/article/256426/dermatology/toddler-presents-patchy-hair-loss
MDedge Pediatrics; Michael Haft, MD, Lawrence F. Eichenfield, MD

Jul 21st, 2022 - Given the history of sudden hair loss, with the exam revealing a well-circumscribed patch of focal alopecia without cutaneous inflammation, hairs with a narrow base and broad distal shaft, the diagnosis is alopecia areata (AA). Alopecia areata (AA.

Baricitinib's Approval for Alopecia Areata: Considerations for Starting Patients on Treatment
https://www.medscape.com/viewarticle/976527

Jul 1st, 2022 - Dermatologists, who recently celebrated the US Food and Drug Administration's (FDA's) approval of the world's first oral systemic treatment for adults with severe alopecia areata (AA), are now looking ahead to the practicalities of getting the dru...

see more →

Patient Education  12 results see all →